Our top pick for
XTL Biopharmaceuticals Ltd is a biotechnology business based in the US. XTL Biopharmaceuticals shares (XTLB) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$0.63 - $4.17|
|50-day moving average||$3.41|
|200-day moving average||$2.64|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.20|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing XTL Biopharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XTL Biopharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XTL Biopharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, XTL Biopharmaceuticals shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||$0|
|Return on assets TTM||-8.06%|
|Return on equity TTM||-29.71%|
|Market capitalisation||$18.7 million|
TTM: trailing 12 months
There are currently 28,167 XTL Biopharmaceuticals shares held short by investors – that's known as XTL Biopharmaceuticals's "short interest". This figure is 460.1% up from 5,029 last month.
There are a few different ways that this level of interest in shorting XTL Biopharmaceuticals shares can be evaluated.
XTL Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of XTL Biopharmaceuticals shares currently shorted divided by the average quantity of XTL Biopharmaceuticals shares traded daily (recently around 31296.666666667). XTL Biopharmaceuticals's SIR currently stands at 0.9. In other words for every 100,000 XTL Biopharmaceuticals shares traded daily on the market, roughly 900 shares are currently held short.
However XTL Biopharmaceuticals's short interest can also be evaluated against the total number of XTL Biopharmaceuticals shares, or, against the total number of tradable XTL Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XTL Biopharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 XTL Biopharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable XTL Biopharmaceuticals shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against XTL Biopharmaceuticals.
Find out more about how you can short XTL Biopharmaceuticals stock.
We're not expecting XTL Biopharmaceuticals to pay a dividend over the next 12 months.
XTL Biopharmaceuticals's shares were split on a 1:5 basis on 9 February 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XTL Biopharmaceuticals shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for XTL Biopharmaceuticals shares which in turn could have impacted XTL Biopharmaceuticals's share price.
Over the last 12 months, XTL Biopharmaceuticals's shares have ranged in value from as little as $0.625 up to $4.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XTL Biopharmaceuticals's is 0.7603. This would suggest that XTL Biopharmaceuticals's shares are less volatile than average (for this exchange).
XTL Biopharmaceuticals Ltd. , a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.